BMY
Bristol-Myers Squibb Co.
$56.16
-0.16%
2026-05-08
About Bristol-Myers Squibb Co.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Key Fundamentals
P/E Ratio
15.73
Forward P/E
9.14
EPS (TTM)
$3.57
ROE
38.7%
Revenue Growth (YoY)
2.6%
Profit Margin
15.0%
Debt/Equity
230.97
Dividend Yield
4.5%
Price/Book
5.71
Beta
0.26
Market Cap
$114.69B
Avg Volume (10D)
11.8M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$62.89
60D Low
$55.57
Avg Volume
9.4M
Latest Close
$56.16
Get breakout alerts for BMY
Sign up for Breakout Scanner to receive daily notifications when BMY triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Bristol-Myers Squibb Co. (BMY) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors BMY daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. BMY operates in the Healthcare sector within the Drug Manufacturers - General industry. Data is provided for informational purposes only and does not constitute financial advice.